Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.64 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13593831 | 0.92 | MAPK14 (0.84) | MAPK14LIMK1LIMK2 | |
| SCHEMBL13593851 | 0.90 | MAPK14 (0.82) | MAPK14LIMK1LIMK2 | |
| SCHEMBL1617299 | 0.90 | MAPK14 (1.00) | MAPK14LIMK1LIMK2 | |
| SCHEMBL1616652 | 0.90 | MAPK14 (0.88) | MAPK14LIMK1LIMK2 | |
| SCHEMBL12715841 | 0.89 | MAPK14 (0.81) | MAPK14LIMK1LIMK2 | |
| SCHEMBL1615977 | 0.89 | MAPK14 (1.00) | MAPK14LIMK1LIMK2 | |
| SCHEMBL12715845 | 0.88 | MAPK14 (0.79) | MAPK14LIMK1LIMK2 | |
| SCHEMBL12715843 | 0.88 | MAPK14 (0.79) | MAPK14LIMK1LIMK2 | |
| SCHEMBL12715830 | 0.88 | MAPK14 (0.79) | MAPK14LIMK1LIMK2 | |
| SCHEMBL12715819 | 0.88 | MAPK14 (0.79) | MAPK14LIMK1LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923556-B2 | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923556-B2 | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923556-B2 | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100029649-A1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-04 | — | — | US | disclosed |
| US-20100029649-A1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-04 | — | — | US | disclosed |
| US-20100029649-A1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-04 | — | — | US | disclosed |
| EP-1848714-B1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-1848714-B1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20060178388-A1 | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029649-A1 | PHENYL-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | LIMK1, LIMK2, MAPK1 | MAPK14 83/4885LIMK1 1/4885LIMK2 2/4885 |
| US-20060178388-A1 | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors | LIMK1, LIMK2, MAPK1 | MAPK14 83/4885LIMK1 1/4885LIMK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.